Table of Contents:

• Introduction to Combat BRS

• How the Combat BRS System Works

• Clinical Benefits for NMIBC Patients

• Combat BRS in Swiss Urology Clinics

• Scientific Evidence Supporting Combat BRS

• Conclusion

Introduction to Combat BRS

Combat BRS is a state-of-the-art system designed for the delivery of Hyperthermic Intravesical Chemotherapy (HIVEC®), offering new hope for patients diagnosed with Non-Muscle Invasive Bladder Cancer (NMIBC). Widely adopted in leading Swiss hospitals, Combat BRS combines precision heating with controlled drug instillation, optimizing cancer treatment outcomes.

In Switzerland, the Combat BRS system is distributed by leading medical providers, such as Innomedicus, ensuring hospitals and urology clinics have access to the latest therapeutic innovations.

How the Combat BRS System Works

The Combat BRS system works by circulating heated chemotherapeutic agents inside the bladder. By elevating the temperature to 43°C, it enhances the penetration and cytotoxic effect of mitomycin-C (MMC) on bladder cancer cells. The BRS (Bladder Recirculation System) includes a heating unit, temperature monitors, and a closed-loop circuit for safe and consistent delivery.

Heating Unit - Maintains optimal 43°C temperature
Peristaltic Pump - Ensures stable flow of chemo solution
Closed System - Prevents drug leakage and exposure

Clinical Benefits for NMIBC Patients

• Enhanced efficacy of mitomycin-C

• Minimally invasive and well-tolerated

• Proven to reduce recurrence in NMIBC

• Shorter treatment duration compared to traditional BCG

Numerous clinical trials across Europe, including Switzerland, confirm that Combat BRS significantly improves outcomes for high-risk NMIBC patients who either cannot tolerate or are resistant to BCG therapy.

Combat BRS in Swiss Urology Clinics

In Swiss clinical settings, urologists are increasingly implementing Combat BRS as a front-line treatment for intermediate and high-risk bladder cancer. Its portability, ease of use, and patient comfort make it ideal for both hospital and outpatient environments.

In addition, Swiss medical institutions value the system’s compliance with local and EU medical safety standards, making it a reliable and future-proof investment in cancer therapy infrastructure.

Scientific Evidence Supporting Combat BRS

Published studies in top urology journals demonstrate the superiority of hyperthermic intravesical chemotherapy over standard chemo instillation. Data shows:

• Up to 60% reduction in recurrence rates

• Improved disease-free survival over 24 months

• Comparable safety to cold MMC but better efficacy

Leading Swiss urologists also report improved quality of life and better adherence to treatment protocols thanks to the system's tolerability.

Conclusion

The Combat BRS system represents a breakthrough in bladder cancer treatment, offering a more effective alternative to traditional methods, especially for NMIBC. Its clinically validated mechanism, ease of integration into existing clinical workflows, and strong support from Swiss healthcare providers position it as a gold standard in hyperthermic intravesical chemotherapy.

For more information and technical specifications, visit the official page here: Combat BRS – Innomedicus Switzerland.